PROSTATE CANCER (ADENOCARCINOMA)
Clinical trials for PROSTATE CANCER (ADENOCARCINOMA) explained in plain language.
Never miss a new study
Get alerted when new PROSTATE CANCER (ADENOCARCINOMA) trials appear
Sign up with your email to follow new studies for PROSTATE CANCER (ADENOCARCINOMA), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill HLD-0915 takes on tough prostate cancer
Disease control Recruiting nowThis study tests an experimental oral drug called HLD-0915 in men with metastatic prostate cancer that has worsened after other treatments. The trial has two phases: Phase 1 checks safety and the best dose, while Phase 2 looks at how well it controls the cancer. About 190 men wil…
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Phase: PHASE1, PHASE2 • Sponsor: Halda Therapeutics OpCo, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for tough prostate cancer: drug combo aims to delay progression
Disease control Recruiting nowThis study tests whether the drug talazoparib, given alone or with enzalutamide, can slow down cancer growth in men with a certain type of advanced prostate cancer that has stopped responding to a previous treatment called abiraterone. About 126 participants with specific gene ch…
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Phase: PHASE2 • Sponsor: Prostate Cancer Clinical Trials Consortium • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New trial: could adding chemo to hormone therapy stop prostate cancer from spreading?
Disease control Recruiting nowThis phase 3 trial is testing whether adding the chemotherapy drug docetaxel to standard hormone therapy (ADT plus an ARPI) can lower the chance of prostate cancer growing or spreading. The study enrolls 830 men with metastatic prostate cancer that is sensitive to hormone therapy…
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Phase: PHASE3 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New pill takes on Hard-to-Treat prostate cancer in early human trial
Disease control Recruiting nowThis early-phase study is testing a new daily pill called ACE-232 in 67 men with metastatic castration-resistant prostate cancer that has stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see early signs of whether …
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Phase: PHASE1 • Sponsor: Acerand Therapeutics (Hong Kong) Limited • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Major trial tests best way to boost radiation for prostate cancer
Disease control Recruiting nowThis study is testing whether adding a focused radiation boost after standard short-course radiotherapy improves outcomes for men with localized prostate cancer. About 1,200 men will be randomly assigned to receive either standard SBRT alone or SBRT plus one of three boost method…
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Phase: PHASE2, PHASE3 • Sponsor: Affidea Nu-med Center of Oncological DIagnostics and Therapy • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New gene therapy injection aims to boost prostate cancer radiation results
Disease control Recruiting nowThis study tests a gene therapy called aglatimagene besadenovec, given with valacyclovir, in 45 men with intermediate-risk prostate cancer who will also receive radiation. The main goal is to see how the therapy spreads in the body and to measure immune responses and tumor marker…
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Phase: PHASE2 • Sponsor: Candel Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New combo therapy aims to boost prostate cancer fight before surgery
Disease control Recruiting nowThis study tests whether giving a high dose of internal radiation (brachytherapy) before robotic prostate surgery can safely improve outcomes for men with high-risk prostate cancer. About 29 participants will receive the radiation, then surgery, and possibly short-term hormone th…
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Phase: PHASE1, PHASE2 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Gut bacteria may hold key to reversing prostate cancer drug resistance
Disease control Recruiting nowThis study tests whether adding dexamethasone or metronidazole to standard therapy can restore sensitivity to abiraterone in men with metastatic prostate cancer that has stopped responding. About 58 men whose cancer progressed on abiraterone will receive either dexamethasone or d…
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
One and done? new prostate cancer radiotherapy trial aims to cut treatment to a single session
Disease control Recruiting nowThis study is testing whether a single, high-dose radiotherapy session can safely control prostate cancer in men with intermediate or high-risk disease. About 58 participants will receive one focused radiation dose to the tumor, guided by MRI and imaging. The goal is to see if th…
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Sponsor: University of Milano Bicocca • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New adaptive radiation aims to spare bladder in prostate cancer patients
Disease control Recruiting nowThis study is testing a new type of radiation therapy that adapts to changes in the prostate and bladder during each treatment session. It is for men with localized prostate cancer who also have an enlarged prostate or urinary symptoms. The goal is to see if this approach can red…
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Sponsor: University of Zurich • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug cocktail aims to shrink prostate tumors before surgery
Disease control Recruiting nowThis early-phase trial is testing whether a combination of two hormone-blocking drugs (darolutamide and relugolix) can safely shrink high-risk prostate tumors before they are surgically removed. About 30 men with aggressive prostate cancer will take the drugs for a short time bef…
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Phase: PHASE1 • Sponsor: AdventHealth • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Could adaptive radiation make prostate cancer treatment safer?
Disease control Recruiting nowThis study is testing a new way to deliver radiation for prostate cancer that adapts to daily changes in the body. It involves 100 men with low- or intermediate-risk prostate cancer. The goal is to see if this approach can better protect nearby organs and improve quality of life.
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Phase: NA • Sponsor: Clinique Sainte Clotilde • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Laser zaps prostate tumors without major surgery
Disease control Recruiting nowThis study tests a new, less invasive way to treat intermediate-risk prostate cancer using a laser guided by micro-ultrasound. The goal is to see if the procedure is safe and can delay or avoid the need for more aggressive treatments like surgery or radiation. Seven men aged 40-8…
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New radiation technique aims to zap prostate cancer with fewer side effects
Disease control Recruiting nowThis study is testing a new type of radiation therapy called adaptive SBRT for men with intermediate- or favorable high-risk prostate cancer. The goal is to see if it can safely deliver a higher dose of radiation directly to the tumor while avoiding nearby organs, which may reduc…
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Phase: NA • Sponsor: Fox Chase Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug duo takes on tough prostate cancers
Disease control Recruiting nowThis phase 2 trial is testing a combination of two drugs—sacituzumab tirumotecan and tagitanlimab—in people with aggressive variant or neuroendocrine prostate cancer that has progressed after prior treatments. The study aims to see if the combo can shrink tumors and delay disease…
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Phase: PHASE2 • Sponsor: Tianjin Medical University Second Hospital • Aim: Disease control
Last updated Jun 26, 2026 18:44 UTC
-
New laser microscope could help surgeons save nerves during prostate cancer surgery
Diagnosis Recruiting nowThis study tests a new microscope called LaserSAFE that scans the removed prostate during surgery to see if cancer cells are at the edge. If it works well, surgeons can decide right away whether to spare nearby nerves. About 693 men with prostate cancer will take part, and the st…
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Phase: NA • Sponsor: University College, London • Aim: Diagnosis
Last updated Jun 27, 2026 12:35 UTC
-
New scan could spot returning prostate cancer at Ultra-Low PSA levels
Diagnosis Recruiting nowThis study is testing whether a special PET scan using flotufolastat F 18 can detect prostate cancer that has come back after surgery, even when PSA levels are very low (0.20 ng/mL or less). Researchers will scan 50 men with a history of prostate cancer and a rising PSA after pro…
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Sponsor: Massachusetts General Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:32 UTC
-
Could a special PET scan spot returning prostate cancer sooner?
Diagnosis Recruiting nowThis study is testing whether adding a PSMA PET scan to the usual MRI can better detect prostate cancer that has come back after focal therapy. Focal therapy treats only the cancerous part of the prostate, but cancer can sometimes return. The PSMA PET scan uses a radioactive dye …
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Phase: NA • Sponsor: University of Chicago • Aim: Diagnosis
Last updated Jun 27, 2026 09:05 UTC
-
Promising new imaging probes could spot prostate cancer missed by standard scans
Diagnosis Recruiting nowThis study tests two new imaging agents (68Ga-G21 and 68Ga-G23) that target a protein found on most prostate cancer cells. The goal is to see if these PET scans can find cancers that standard PSMA scans might miss, helping doctors better stage the disease and guide treatment. Six…
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Phase: PHASE1, PHASE2 • Sponsor: First Affiliated Hospital of Fujian Medical University • Aim: Diagnosis
Last updated Jun 27, 2026 08:13 UTC
-
New PET scan could outshine MRI for prostate cancer detection
Diagnosis Recruiting nowThis study aims to see if a special PET scan (68Ga-PSMA-11) is better than standard MRI at finding prostate tumors in people who have just been diagnosed and haven't started treatment. About 100 participants will receive both scans before surgery, and the results will be checked …
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Phase: PHASE2, PHASE3 • Sponsor: First Affiliated Hospital of Fujian Medical University • Aim: Diagnosis
Last updated Jun 27, 2026 07:53 UTC
-
New PET scan agent could outshine MRI for prostate cancer detection
Diagnosis Recruiting nowThis study is testing a new radioactive tracer called 68Ga-P16-093 for PET scans to see how well it finds prostate cancer tumors compared to standard MRI scans. About 50 people with newly diagnosed, untreated prostate cancer will receive both scans before their prostate removal s…
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Phase: PHASE1, PHASE2 • Sponsor: First Affiliated Hospital of Fujian Medical University • Aim: Diagnosis
Last updated Jun 27, 2026 07:53 UTC
-
Powder during prostate surgery may cut bleeding and save sexual function
Symptom relief Recruiting nowThis study tests whether applying a powder called ARISTA AH during robotic prostate removal can reduce blood loss and help preserve erectile function. About 362 men with prostate cancer will be randomly assigned to receive the powder or standard care. The goal is to see if the po…
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Phase: NA • Sponsor: St. Antonius Hospital Gronau • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Learning together: new program aims to help couples face prostate cancer
Symptom relief Recruiting nowThis study tests an 8-week program where prostate cancer patients and their spouses learn and support each other using a handbook, a mobile app, and professional guidance. The goal is to improve physical symptoms, emotional well-being, and family resilience. Sixty couples will be…
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Phase: NA • Sponsor: National Taipei University of Nursing and Health Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
New hope for men battling hot flashes from prostate cancer treatment
Symptom relief Recruiting nowThis study tests a drug called fezolinetant to see if it can reduce hot flashes in men with prostate cancer who are on hormone therapy (androgen deprivation therapy). About 60 men will take either the drug or a placebo daily for 4 weeks. Researchers will track hot flash frequency…
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Phase: PHASE2 • Sponsor: Shehzad Basaria, M.D. • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Can less radiation to healthy prostate cut side effects?
Symptom relief Recruiting nowThis study tests whether giving a lower radiation dose to healthy parts of the prostate, while keeping a high dose to visible tumors, can reduce bowel and urinary side effects in men with low or intermediate-risk prostate cancer. Participants will receive two sessions of MRI-guid…
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Phase: NA • Sponsor: The Netherlands Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 09:02 UTC
-
New genetic test may predict prostate cancer drug response before surgery
Knowledge-focused Recruiting nowThis study is testing whether a new genetic test (called PCAI ImmunoScore) can predict how well men with high-risk prostate cancer will respond to the drug darolutamide before surgery. About 100 participants will take darolutamide for 3-4 months, then have their prostate removed.…
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Phase: PHASE2 • Sponsor: Region Stockholm • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Prostate cancer study asks men: what do you think about breast side effects?
Knowledge-focused Recruiting nowThis study interviews 24 men with prostate cancer to learn how they feel about breast-related side effects, such as gynecomastia (enlarged breasts), from treatment. The goal is to understand what matters most to patients when choosing therapies. Results will help design a future …
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Phase: NA • Sponsor: St Vincent's Hospital, Sydney • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Algerian prostate cancer study seeks 2,000 men
Knowledge-focused Recruiting nowThis study aims to describe the characteristics of prostate cancer in Algeria, including patient demographics, symptoms, diagnosis methods, and treatments. Researchers will collect data from 2,000 men aged 19 and older with confirmed prostate cancer. The goal is to better underst…
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Sponsor: Société Algérienne de Formation et Recherche en Oncologie • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC
-
PSA after prostate surgery: a crystal ball for cancer?
Knowledge-focused Recruiting nowThis study follows 500 men who had their prostate removed for cancer. Researchers check PSA levels soon after surgery to see if they can predict if the cancer will come back or spread. No new treatments are given—just standard care and observation.
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Sponsor: Lithuanian University of Health Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Personalized radiation dosing may improve prostate cancer therapy
Knowledge-focused Recruiting nowThis study looks at whether measuring the exact radiation dose delivered to tumors can predict which patients with advanced prostate cancer will respond to a targeted radioactive therapy called Lu-177 PSMA. Researchers will track 110 men over 12 weeks to see if dose calculations …
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Sponsor: Jules Bordet Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
3D model helps surgeons target cancer spread in prostate patients
Knowledge-focused Recruiting nowThis study tests whether a 3D virtual model, created from PSMA PET scans, can help surgeons better remove lymph node metastases in prostate cancer patients. About 102 participants will undergo surgery with the model used for planning and guidance. Researchers will measure how man…
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Phase: NA • Sponsor: Martini-Klinik am UKE GmbH • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC